Cargando…
Role of Peroxisome Proliferator-Activated Receptor Alpha in the Control of Cyclooxygenase 2 and Vascular Endothelial Growth Factor: Involvement in Tumor Growth
A growing body of evidence indicates that PPAR (peroxisome proliferator-activated receptor) α agonists might have therapeutic usefulness in antitumoral therapy by decreasing abnormal cell growth, and reducing tumoral angiogenesis. Most of the anti-inflammatory and antineoplastic properties of PPAR l...
Autores principales: | Grau, Raquel, Díaz-Muñoz, Manuel D., Cacheiro-Llaguno, Cristina, Fresno, Manuel, Iñiguez, Miguel A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2490577/ https://www.ncbi.nlm.nih.gov/pubmed/18670614 http://dx.doi.org/10.1155/2008/352437 |
Ejemplares similares
-
Regulation of Cyclooxygenase-2 Expression in Human T Cells by Glucocorticoid Receptor-Mediated Transrepression of Nuclear Factor of Activated T Cells
por: Cacheiro-Llaguno, Cristina, et al.
Publicado: (2022) -
Selective Inhibition of Vascular Endothelial Growth Factor–Mediated Angiogenesis by Cyclosporin a: Roles of the Nuclear Factor of Activated T Cells and Cyclooxygenase 2
por: Hernández, Gabriela L., et al.
Publicado: (2001) -
Peroxisome proliferator-activated receptor alpha agonist suppresses neovascularization by reducing both vascular endothelial growth factor and angiopoietin-2 in corneal alkali burn
por: Arima, Takeshi, et al.
Publicado: (2017) -
Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma
por: Kwon, Soon Ha, et al.
Publicado: (2012) -
Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma
por: Prins, M. J. D., et al.
Publicado: (2012)